SRS for BS lesion: what dose?

young female, known to have a metastatic breast cancer, since 5 years. In 2017, she developed secondary lesions in the brain with positive CSF. She receives 30Gy/10 fr whole brain radiation, with intra-thecal chemotherapy. A month ago, she developed gait disturbances with blurred speech an hemifacial paresia. Brain MRI showed a solitary secondary lesion, 1.5 cm involving the left middle cerebral peduncle with extensive edema. No signs of meningeal disease. Pet CT : NED outside the brain... SRS for BS lesion: what dose?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums

Related Links:

In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Doctors have gotten much better at detecting and treating breast cancer early. Drug and chemotherapy regimens to control tumors have gotten so effective, in fact, that in some cases, surgery is no longer necessary. In up to 30% of cases of early-stage breast cancer treated before surgery, doctors can’t find evidence of cancer cells in postoperative biopsies. The problem, however, is that there is currently no reliable way to tell which cancers have been pushed into remission and which ones have not. That’s where an easy identifier, like a blood test, could transform the way early stage breast cancer is treated....
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized blood tests Breast Cancer Source Type: news
Publication date: Available online 2 August 2019Source: European Journal of Surgical OncologyAuthor(s): Mariko Asaoka, Kazutaka Narui, Nobuyasu Suganuma, Takashi Chishima, Akimitsu Yamada, Sadatoshi Sugae, Saori Kawai, Natsuki Uenaka, Saeko Teraoka, Kana Miyahara, Takahiko Kawate, Eichi Sato, Toshitaka Nagao, Yuka Matsubara, Shipra Gandhi, Kazuaki Takabe, Takashi IshikawaAbstractIntroductionDespite the excellent prognosis associated with pathological complete response (pCR) to neoadjuvant chemotherapy (NAC), some patients still develop recurrence. Here, we investigated the outcomes of breast cancer patients with pCR, as we...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
In this study, we investigated local (tumor) and peripheral (blood) cellular immunome of patients with melanoma, breast cancer and brain cancer using a rapid and reliable standardized, multiparameter flow cytometry assay. We used this approach to monitor changes in the peripheral cellular immunome in women with breast cancer undergoing SOC therapy. Our analysis is unique because it is conducted using matched fresh tumor tissue and blood from patients in real-time, within 2-3 hours of sample acquisition, and provides insight into the innate and adaptive immune cell profile in blood and tumor. Specific to blood, this approac...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsThe combination of irinotecan and temozolomide was well tolerated, demonstrated some clinical activity across multiple breast cancer subtypes with progressing CNS disease, and offers a reasonable option for patients who are not candidates for further radiation or clinical trials.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
In this study, we intend to include a large sample and investigate cardiac function through serial measures of biomarkers and imaging techniques.MethodsThis protocol describes a two-arm, prospective, randomized controlled trial that will explore the cardioprotective effect of a structured exercise program in women with BC undergoing anthracycline-containing chemotherapy (ACT). Ninety adult women with early BC and recommended to receive ACT will be randomly assigned (1:1) to an intervention group or a control group. Patients allocated to the intervention group will perform a supervised exercise program three times per week,...
Source: Trials - Category: Research Source Type: clinical trials
Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
In this study, we evaluate the evolution of cardiac changes during a three-year follow-up after adjuvant breast radiotherapy (RT). Methods: Sixty patients with left-sided and 20 patients with right-sided early stage breast cancer without chemotherapy were included in this prospective study. Echocardiography and cardiac biomarkers were evaluated before, immediately after and 3 years after RT. Radiation doses to cardiac structures were calculated. Results: In echocardiography, left ventricle (LV) systolic measurements had impaired at 3 years compared to baseline: the mean global longitudinal strain (GLS) worsened from -18&th...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
AbstractPurposeTo evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.Materials and methodsWe conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L –T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.ResultsOne hundred and fifteen patients from 14 institutions were included. The median age was 59.8  years. The median nu...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A Abstract PURPOSE: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. MATERIALS AND METHODS: We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L-T. Concomitant endocrine therapy, as well as brain metastasis and/or prior ...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Men | Neurology | Students | Universities & Medical Training